Hemolysis after Transfusion of Blood Products with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

Hemolysis after Transfusion of Blood Products with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: A Randomized trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210823006

Enrollment

Registered

2021-08-23

Start date

2020-04-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with pure underproduction anemia who required blood transfusion without previous G6PD deficiency Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, Blood transfusion, Hemolysis

Interventions

G6PD deficiency LPRC will given to patient that meet inclusion criteria,G6PD normal LPRC will given to patient that meet inclusion criteria

Experimental Other,Experimental Other

G6PD deficiency LPRC,G6PD normal LPRC

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >18 yrs. 2. Require blood transfusion (Hb <8.0 g/dL or anemic symptoms) 3. pure underproduction anemia

Exclusion criteria

Exclusion criteria: 1. anemia from blood loss or hemolysis 2. G6PD deficiency patients 3. Receiving medications which might induce hemolysis in G6PD deficiency within one week

Design outcomes

Primary

Measure	Time frame
Hemolysis at 48 hr after intervention measurements of pre- and post-transfusion indirect bilirubin, LDH and haptoglobin	—

Secondary

Measure	Time frame
Hb rising at 48 hr after intervention measurements of pre- and post-transfusion Hb and Hct	—

Countries

Thailand

Contacts

Public ContactSuphattharachai Krajibthong

Hua Hin hospital

suphattharachai.k@gmail.com66867738952

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026